



Better Health, Brighter Future

Date: February 22, 2024

To: Office of the Attorney General of Vermont

Re: Vermont New Drug Notice

Via Email: AGO.highcostprescriptiondrugs@vermont.gov

Pursuant to 18 V.S.A. § 4637(b), Takeda Pharmaceuticals America is providing notice of the introduction of a new prescription drug with a Wholesale Acquisition Cost that exceeds the threshold set for a specialty drug under the Medicare Part D program on February 20, 2024.

The new product being launched is:

Eohilia Oral Suspension 2 MG/10ML, NDC 64764-0105-60

Sincerely,

Jessica Blain

Associate Director, Contracts and Pricing Compliance

Takeda Pharmaceuticals America, Inc.

Email: jessica.blain@takeda.com